

A Highly Efficient and Green Method for the Synthesis of 3,4-Dihydropyrimidin-2-ones and 1,5-Benzodiazepines Catalyzed by Dodecyl Sulfonic Acid in Water

Saikat Das Sharma, Pranjal Gogoi and Dilip Konwar*

Organic Chemistry Division, Regional Research Laboratory, Jorhat –785006, Assam, India

dkonwar @yahoo.co.uk

Supporting Information


Table of Contents:

| | |
|--|-----|
| General Information | S2 |
| General Procedure for the formation of 3,4-dihydropyrimidin-2-ones | S2 |
| Characterization data for compounds 4 (a) | S2 |
| Characterization data for compounds 4 (b -d) | S3 |
| Characterization data for compounds 4 (e-g) | S4 |
| Characterization data for compounds 4 (h-j) | S5 |
| Characterization data for compounds 4(k-m) | S6 |
| Characterization data for compounds 4(n-p) | S7 |
| General Procedure for the formation of 1,5-benzodiazepines | S8 |
| Characterization data for compounds 7(a-b) | S8 |
| Characterization data for compounds 7(c-e) | S9 |
| Characterization data for compounds 7(f-h) | S10 |

General Information

^1H NMR spectra were recorded on 300 MHz. Chemical shifts are expressed in δ units relative to tetramethylsilane (TMS) signal as internal reference in DMSO-d_6 or CDCl_3 . FT-IR spectra were recorded in CHCl_3 or on KBr pellets. Column chromatography was performed on silica gel (60-120 mesh) using ethyl acetate and hexane as eluent.


General Procedure for the formation of 3,4-dihydropyrimidin-2-ones:



In a 50 ml round-bottom flask, aldehyde (2 mmol), ethyl acetoacetate (2 mmol) and urea (3 mmol) were stirred in presence of dodecyl sulfonic acid (10 mol %) in H_2O (10 ml) at the room temperature for the stipulated time. The progress of the reaction was monitored by TLC. After completion of the reaction, the solid separated was filtered, washed with water (5x10 ml), dried under vacuum and recrystallized from ethanol to afford pure product.


Spectral Data of the 3,4-Dihydropyrimidin-2-ones and thiones Obtained by the Condensation of Aldehydes, 1,3-Dicarbonyls and Urea:

4a. 5-(Ethoxycarbonyl)-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-one:




M.P. 202-203 $^{\circ}\text{C}$; ^1H NMR (DMSO , 300MHz): δ 1.08 (t, 3H), 2.23 (s, 3H), 3.98 (q, 2H), 5.13 (d, 1H), 7.10-7.29 (m, 5H), 7.81 (s, 1H), 9.15 (s, 1H); FT-IR (KBr, cm^{-1}): 1635.2, 1725.1, 3240.5; MS (m/z): 260.26 (M^+). Anal. Calcd. for $\text{C}_{14}\text{H}_{16}\text{O}_3\text{N}_2$: C, 64.60; H, 6.20; N, 10.76. Found: C, 64.56; H, 6.14; N, 10.74.

4b. 5-(Ethoxycarbonyl)-6-methyl-4-(4-methylphenyl)-3,4-dihydropyrimidin-2(1H)-one:




M.P.214-216 °C; ^1H NMR (DMSO, 300MHz): δ 1.07 (t, 3H), 2.22 (s, 3H), 2.29 (s, 3H), 4.00 (q, 2H), 5.10 (s, 1H), 7.15-7.19 (m, 4H), 7.80 (s, 1H), 9.18 (s, 1H); FT-IR (KBr, cm^{-1}): 1633.8, 1715.9, 3241.5; MS (m/z): 274.37 (M^+). Anal. Calcd. for $\text{C}_{15}\text{H}_{18}\text{O}_3\text{N}_2$: C, 65.68; H, 6.61; N, 10.21. Found: C, 65.61; H, 6.65; N, 10.17.

4c. 5-(Ethoxycarbonyl)-4-(4-methoxyphenyl)- 6-methyl-3,4-dihydropyrimidin-2(1H)-one:




M.P.200-201 °C; ^1H NMR (DMSO, 300MHz): δ 1.10 (t, 3H), 2.25 (s, 3H), 3.73 (s, 3H), 3.98 (q, 2H), 5.16 (s, 1H), 7.01-7.21 (m, 4H), 7.73 (s, 1H), 9.19 (s, 1H); FT-IR (KBr, cm^{-1}): 1635.7, 1717.5, 3242.1; MS (m/z): 290.39 (M^+). Anal. Calcd. for $\text{C}_{15}\text{H}_{18}\text{O}_4\text{N}_2$: C, 62.06; H, 6.25; N, 9.65. Found: C, 62.11; H, 6.16; N, 9.72.

4d. 5-(Ethoxycarbonyl)-6-methyl-4-(4-nitrophenyl)-3,4-dihydropyrimidin-2(1H)-one:




M.P.208-209 °C; ^1H NMR (DMSO, 300MHz): δ 1.09 (t, 3H), 2.24 (s, 3H), 3.76 (q, 2H), 5.19 (d, 1H), 7.62-8.10 (m, 4H), 7.92 (s, 1H), 9.28 (s, 1H); FT-IR (KBr, cm^{-1}): 1644.2, 1723.6, 3240.0; MS (m/z): 305.20 (M^+). Anal. Calcd. for $\text{C}_{14}\text{H}_{15}\text{O}_5\text{N}_3$: C, 55.08; H, 4.95; N, 13.76. Found: C, 55.17; H, 4.88; N, 13.62.

4e. 4-(4-Chlorophenyl)-5-(ethoxycarbonyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one:




M.P. 210-211 °C; ¹H NMR (DMSO, 300MHz): δ 1.10 (t, 3H), 2.25 (s, 3H), 3.89 (q, 2H), 5.16 (s, 1H), 7.31-7.50 (m, 4H), 7.80 (s, 1H), 9.25 (s, 1H); FT-IR (KBr, cm⁻¹): 1644.0, 1723.1, 3239.7; MS (m/z): 294.79 (M⁺). Anal. Calcd. for C₁₄H₁₅O₃N₂Cl: C, 57.05; H, 5.13; N, 9.50. Found: C, 57.12; H, 5.04; N, 9.45.

4f. 5-(Ethoxycarbonyl)-4-(3-hydroxyphenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one:




M.P. 163-164 °C; ¹H NMR (DMSO, 300MHz): δ 1.09 (t, 3H), 2.22 (s, 3H), 4.01 (q, 2H), 5.05 (d, 1H), 6.6 (s, 1H), 6.51-7.06 (m, 4H), 7.71 (s, 1H), 9.17 (s, 1H), 9.36 (s, 1H); FT-IR (KBr, cm⁻¹): 1644.2, 1723.6, 3240.0; MS (m/z): 276.23 (M⁺). Anal. Calcd. for C₁₄H₁₆O₄N₂: C, 60.86; H, 5.84; N, 10.14. Found: C, 60.79; H, 5.88; N, 10.10.

4g. 5-(Ethoxycarbonyl)-6-methyl-4-(n-propyl)-3,4-dihydropyrimidin-2(1H)-one:




M.P. 152-153 °C; ¹H NMR (DMSO, 300MHz): δ 0.90 (t, 3H), 1.27 (t, 3H), 1.41-1.58 (m, 4H), 2.29 (s, 3H), 4.14 (q, 2H), 4.91 (s, 1H), 7.53 (s, 1H), 9.04 (s, 1H); FT-IR (KBr, cm⁻¹): 1646.2, 1705.8, 3246.6; MS (m/z): 226.22 (M⁺). Anal. Calcd. for C₁₁H₁₈O₃N₂: C, 58.39; H, 8.02; N, 12.38. Found: C, 58.31; H, 8.10; N, 12.30.

4h. 5-(Ethoxycarbonyl)-4-(*iso*-propyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one:




M.P. 170-171 °C; ¹H NMR (DMSO, 300MHz): δ 0.76-0.81 (m, 6H), 1.07 (t, 3H), 1.69 (m, 1H), 2.19 (s, 3H), 4.02 (q, 2H), 4.89 (s, 1H), 7.54 (s, 1H), 9.00 (s, 1H); FT-IR (KBr, cm⁻¹): 1642.0, 1709.5, 3235.0; MS (m/z):226.21 (M⁺). Anal. Calcd. for C₁₁H₁₈O₃N₂: C, 58.39; H, 8.02; N, 12.38. Found: C, 58.33; H, 8.08; N, 12.30.

4i. 5-(Ethoxycarbonyl)-4-(2-furyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one:




M.P. 203-204 °C; ¹H NMR (DMSO, 300MHz): δ 1.12 (t, 3H), 2.21 (s, 3H), 4.02 (q, 2H), 5.18 (d, 1H), 6.4-7.5 (m, 3H), 7.76 (s, 1H), 9.20 (s, 1H); FT-IR (KBr, cm⁻¹): 1644.0, 1706.1, 3240.2; MS (m/z):250.29 (M⁺). Anal. Calcd. for C₁₂H₁₄O₄N₂: C, 57.59; H, 5.64; N, 11.19. Found: C, 57.65; H, 5.70; N, 11.27.

4j. 5-(Ethoxycarbonyl)-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-thione:




M.P. 207-209 °C; ¹H NMR (DMSO, 300MHz): δ 1.09 (t, 3H), 2.27 (s, 3H), 3.99 (q, 2H), 5.15 (d, 1H), 7.20-7.35 (m, 5H), 9.63 (s, 1H), 10.29 (s, 1H); FT-IR (KBr, cm⁻¹): 1578.3, 1672.7, 3181.2, 3339.8; MS (m/z):276.31 (M⁺). Anal. Calcd. for C₁₄H₁₆O₂N₂S: C, 60.85; H, 5.84; N, 10.14. Found: C, 60.78; H, 5.90; N, 10.08.

4k. 5-(Ethoxycarbonyl)-4-(3-hydroxyphenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-thione:




M.P. 184-185 °C; ¹H NMR (DMSO, 300MHz): δ 1.14 (t, 3H), 2.30 (s, 3H), 4.03 (q, 2H), 5.12 (d, 1H), 6.74-7.12 (m, 4H), 9.42 (s, 1H), 9.64 (s, 1H), 10.31 (s, 1H); FT-IR (KBr, cm⁻¹): 1574.7, 1620.3, 1654.9, 1670.6, 3180.1, 3300.8; MS (m/z): 292.31(M⁺). Anal. Calcd. for C₁₄H₁₆O₃N₂S: C, 57.52; H, 5.52; N, 9.58. Found: C, 57.59; H, 5.47; N, 9.52.

4l. 5-(Ethoxycarbonyl)-6-methyl-4-(4-methoxyphenyl)-3,4-dihydropyrimidin-2(1H)-thione:




M.P. 150-151 °C; ¹H NMR (DMSO, 300MHz): δ 1.09 (t, 3H), 2.26 (s, 3H), 3.72 (s, 3H), 3.99 (q, 2H), 5.11 (s, 1H), 6.88-7.16 (m, 4H), 9.49 (s, 1H), 10.21 (s, 1H); FT-IR (KBr, cm⁻¹): 1561.4, 1599.0, 1651.2, 3250.8; MS (m/z):306.32 (M⁺). Anal. Calcd. for C₁₅H₁₈O₃N₂S: C, 58.80; H, 5.92; N, 9.14. Found: C, 58.74; H, 5.97; N, 9.19.

4m. 5-(Methoxycarbonyl)-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-one:




M.P.207-208 °C; ¹H NMR (DMSO, 300MHz): δ 2.21 (s, 3H), 3.56 (s, 3H), 5.18 (d, 1H), 7.26-7.33 (m, 5H), 7.78 (s, 1H), 9.23 (s, 1H); FT-IR (KBr, cm⁻¹): 1642.0, 1701.1, 3231.8; MS (m/z):246.21 (M⁺). Anal. Calcd. for C₁₃H₁₄O₃N₂: C, 63.40; H, 5.73; N, 11.38. Found: C, 63.33; H, 5.79; N, 11.32.

4n. 5-(Methoxycarbonyl)-6-methyl-4-(4-nitrophenyl)-3,4-dihydropyrimidin-2(1H)-one:




M.P. 235-236 °C; ¹H NMR (DMSO, 300MHz): δ 2.26 (s, 3H), 3.52 (s, 3H), 5.31 (d, 1H), 7.53-8.19 (m, 4H), 7.89 (s, 1H), 9.31 (s, 1H); FT-IR (KBr, cm⁻¹): 1692.8, 1712.6, 3232.4; MS (m/z):291.21 (M⁺). Anal. Calcd. for C₁₃H₁₃O₅N₃: C, 53.61; H, 4.50; N, 14.43. Found: C, 53.56; H, 4.53; N, 14.37.

4o. 5-Aceto-6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-one:




M.P. 233-234 °C; ¹H NMR (DMSO, 300MHz): δ 2.09 (s, 3H), 2.24 (s, 3H), 5.27 (d, 1H), 7.25-7.34 (m, 5H), 7.77 (s, 1H), 9.21 (s, 1H); FT-IR (KBr, cm⁻¹): 1642.9, 1714.7, 3240.8; MS (m/z):230.22 (M⁺). Anal. Calcd. for C₁₃H₁₄O₂N₂: C, 67.81; H, 6.13; N, 12.17. Found: C, 67.77; H, 6.17; N, 12.13.

4p. 5-Aceto-4-(4-chlorophenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one:



M.P. 231-232 °C; ¹H NMR (DMSO, 300MHz): δ 2.18 (s, 3H), 2.31 (s, 3H), 5.15 (s, 1H), 7.25-7.37 (m, 4H), 7.78 (s, 1H), 9.21 (s, 1H); FT-IR (KBr, cm⁻¹): 1642.9, 1714.7, 3240.8; MS (m/z):264.76 (M⁺). Anal. Calcd. for C₁₃H₁₃O₂N₂Cl: C, 58.99; H, 4.95; N, 10.58. Found: C, 58.92; H, 4.89; N, 10.51.


General Procedure for the formation of 1,5-benzodiazepines:



In a 50 ml round-bottom flask, *o*-phenylenediamines (1mmol) and ketones (2.2 mmol) were stirred in presence of dodecyl sulfonic acid (10 mol %) in H₂O (10 ml) at the room temperature. The reaction was monitored by TLC. After completion of the reaction, the product was extracted with ethyl acetate (2 x 25 ml), washed the organic layer with brine (2 x 15 ml), dried over Na₂SO₄ and concentrated. The products were separated and purified by column chromatography on silica gel (60-120 mesh) using ethyl acetate/hexane mixture as eluent to afford pure 1,5-benzodiazepines.


Spectral Data of the 1,5-benzodiazepines Obtained by the Condensation of *o*-Phenylenediamines and ketones:

7a. 2,2,4-Trimethyl-2,3-dihydro-1H-1,5-benzodiazepine:



M.P. 136-137 °C; ¹H NMR (CDCl₃, 300MHz): δ 1.35 (s, 6H), 2.21 (s, 2H), 2.35 (s, 3H), 3.45 (s, 1H), 6.62-7.31 (m, 4H); FT-IR (KBr, cm⁻¹): 3340.4, 1650.8; MS (m/z): 188.21 (M⁺). Anal. Calcd. for C₁₂H₁₆N₂: C, 76.55; H, 8.57; N, 14.88. Found: C, 76.49; H, 8.51; N, 14.80.


7b. 2,4-Diethyl-2-methyl-2,3-dihydro-1H-1,5-benzodiazepine:



M.P. 137-138 °C; ¹H NMR (CDCl₃, 300MHz): δ 0.97 (t, 3H), 1.26 (t, 3H), 1.72 (q, 2H), 2.15 (m, 2H), 2.34 (s, 3H), 2.69 (q, 2H), 3.45 (s, 1H), 6.65-7.33 (m, 4H); FT-IR (KBr, cm⁻¹): 3332.0, 1638.5;


MS (m/z): 216.27 (M^+). Anal. Calcd. for $C_{14}H_{20}N_2$: C, 77.73; H, 9.32; N, 12.95. Found: C, 77.65; H, 9.24; N, 12.83.

7c. 2,2,4-triethyl-3-methyl-2,3-dihydro-1H-1,5-benzodiazepine:




M.P. 143-144 °C; 1H NMR ($CDCl_3$, 300MHz): δ 0.75-1.05 (m, 10H), 1.20-1.40 (m, 4H), 1.48-1.64 (m, 2H), 2.40-2.59 (m, 2H), 2.87 (q, 1H), 3.73 (s, 1H), 6.55 (d, 1H), 6.64 (t, 1H), 6.90 (t, 1H), 7.36 (d, 1H); FT-IR (KBr, cm^{-1}): 3321.0, 1638.2; MS (m/z): 244.29 (M^+). Anal. Calcd. for $C_{14}H_{20}N_2$: C, 78.64; H, 9.90; N, 11.46. Found: C, 78.54; H, 9.80; N, 11.31.

7d. 2-Methyl-2,4-diisobutyl-2,3-dihydro-1H-1,5-benzodiazepine:



M.P. 118-120 °C; 1H NMR ($CDCl_3$, 300MHz): δ 0.95-1.05 (m, 12H), 1.33 (s, 3H), 1.49-1.52 (m, 2H), 1.65-1.75 (m, 1H), 2.05-2.25 (m, 3H), 2.24 (d, 2H), 6.60-6.65 (m, 1H), 6.85-6.95 (m, 2H), 7.05-7.15 (m, 1H); FT-IR (KBr, cm^{-1}): 3330.7, 1637.5; MS (m/z): 272.32 (M^+). Anal. Calcd. for $C_{18}H_{28}N_2$: C, 79.36; H, 10.36; N, 10.28. Found: C, 79.27; H, 10.23; N, 10.19.


7e. 2-Methyl-2,4-diisopropyl-2,3-dihydro-1H-1,5-benzodiazepine:



M.P. 118-119 °C; 1H NMR ($CDCl_3$, 300MHz): δ 0.94 (d, 6H), 1.13 (s, 3H), 1.42 (d, 6H), 1.86 (m, 1H), 2.17 (m, 1H), 2.46-2.54 (d, 1H), 2.57-2.64 (d, 1H), 3.65 (s, 1H), 6.61-7.32 (m, 4H); FT-IR


(KBr, cm^{-1}): 3333.9, 1634.6; MS (m/z): 244.27 (M^+). Anal. Calcd. for $\text{C}_{16}\text{H}_{24}\text{N}_2$: C, 78.64; H, 9.90; N, 11.46. Found: C, 78.53; H, 9.81; N, 11.34.

7f. 2-Methyl-2,4-diphenyl-2,3-dihydro-1H-1,5-benzodiazepine:




M.P. 150-151 °C; ^1H NMR (CDCl_3 , 300MHz): δ 1.80 (s, 3H), 2.95 (d, 1H), 3.16 (d, 1H), 3.44 (s, 1H), 6.53-7.02 (m, 3H), 7.16-7.34 (m, 7H), 7.55-7.65 (m, 4H); FT-IR (KBr, cm^{-1}): 3330.9, 1635.2; MS (m/z): 312.48 (M^+). Anal. Calcd. for $\text{C}_{22}\text{H}_{20}\text{N}_2$: C, 84.58; H, 6.45; N, 8.97. Found: C, 84.51; H, 6.38; N, 8.91.

7g. 10-Spirocyclohexane-2,3,4,10,11,11a-hexahydro-1H-dibenzo[b,e][1,4] diazepine:



M.P. 136-137 °C; ^1H NMR (CDCl_3 , 300MHz): δ 1.23-1.86 (m, 16H), 2.30-2.70 (m, 3H), 4.47 (s, 1H), 6.69-7.70 (m, 4H); FT-IR (KBr, cm^{-1}): 3290.9, 1640.2; MS (m/z): 268.24 (M^+). Anal. Calcd. for $\text{C}_{18}\text{H}_{24}\text{N}_2$: C, 80.55; H, 9.01; N, 10.44. Found: C, 80.46; H, 9.10; N, 10.35.

7h. 2,2,4-Trimethyl-2,3-dihydro-8-methyl-1H-1,5-benzodiazepine:



M.P. 128-129 °C; ^1H NMR (CDCl_3 , 300MHz): δ 1.30 (s, 6H), 2.19 (s, 2H), 2.23 (s, 3H), 2.80 (s, 3H), 6.67 (s, 1H), 6.70-6.80 (m, 1H), 7.05-7.10 (m, 1H); FT-IR (KBr, cm^{-1}): 3325.4, 1665.8; MS (m/z): 202.23 (M^+). Anal. Calcd. for $\text{C}_{13}\text{H}_{18}\text{N}_2$: C, 77.18; H, 8.97; N, 13.85. Found: C, 77.11; H, 8.86; N, 13.79.